Evaluating rational non-cross-resistant combination therapy in advanced clear cell renal cell carcinoma: Combined mTOR and AKT inhibitor therapy

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 1, 2012, Pages 185-194

  Holland, William S ^a   Tepper, Clifford G ^a   Pietri, Jose E ^a   Chinn, Danielle C ^a   Gandara, David R ^a   MacK, Philip C ^a   Lara, Primo N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

AKT; mTOR; Perifosine; Rapamycin; Renal cell cancer

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERLEUKIN 8; KRUPPEL LIKE FACTOR 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PERIFOSINE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA CONTENT; DOSE RESPONSE; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HISTOPATHOLOGY; HUMAN; IC 50; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; RNA ISOLATION; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-8; KIDNEY NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHORYLATION; PHOSPHORYLCHOLINE; PROTO-ONCOGENE PROTEINS C-AKT; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84856739876     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1684-y     Document Type: Article

References (34)

1. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi Z Kovacevic V Lesovoy IG Schmidt-Wolf O Barbarash E Gokmen T O'Toole S Lustgarten L Moore RJ Motzer 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 2281 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
2. RJ Motzer B Escudier S Oudard TE Hutson C Porta S Bracarda V Grunwald JA Thompson RA Figlin N Hollaender G Urbanowitz WJ Berg A Kay D Lebwohl A Ravaud 2008 Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 449 456 18653228 10.1016/S0140-6736(08)61039-9 1:CAS:528:DC%2BD1cXps1GmsLY%3D
3. PH Patel PL Senico RE Curiel RJ Motzer 2009 Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma Clin Genitourin Cancer 7 24 27 19213664 10.3816/CGC.2009.n.004 1:CAS:528:DC%2BD1MXjslKqs70%3D
4. Hainsworth JD, Spigel DR, Burris HA, 3rd, Waterhouse D, Clark BL, Whorf R (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol 28:2131-2136
5. Escudier BJ, Negrier S, G. Gravis, C. Chevreau, R. Delva, J. Bay, L. Geoffrois, E. Legouffe, E. Blanc, C. Ferlay (2010) Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol 28:15s (suppl; abstr 4516)
6. X Wan B Harkavy N Shen P Grohar LJ Helman 2007 Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism Oncogene 26 1932 1940 17001314 10.1038/sj.onc.1209990 1:CAS:528:DC%2BD2sXjtlWgtLw%3D (Pubitemid 46474636)
7. KG Chee J Longmate DI Quinn G Chatta J Pinski P Twardowski CX Pan A Cambio CP Evans DR Gandara PN Lara Jr 2007 The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial Clin Genitourin Cancer 5 433 437 18272025 10.3816/CGC.2007.n. 031 1:CAS:528:DC%2BD1cXitVGqsrk%3D (Pubitemid 351219696)
8. L Van Ummersen K Binger J Volkman R Marnocha K Tutsch J Kolesar R Arzoomanian D Alberti G Wilding 2004 A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer Clin Cancer Res 10 7450 7456 15569974 10.1158/1078-0432.CCR-03-0406 (Pubitemid 39557506)
9. SB Kondapaka SS Singh GP Dasmahapatra EA Sausville KK Roy 2003 Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation Mol Cancer Ther 2 1093 1103 14617782 1:CAS:528:DC%2BD3sXovFCqtLw%3D
10. Engel JB, Schonhals T, Hausler S, Krockenberger M, Schmidt M, Horn E, Koster F, Dietl J, Wischhusen J, Honig A (2011) Induction of programmed cell death by inhibition of AKT with the alkylphosphocholine perifosine in in vitro models of platinum sensitive and resistant ovarian cancers. Arch Gynecol Obstet 283:603-610
11. PR Purnell PC Mack CG Tepper CP Evans TP Green PH Gumerlock PN Lara DR Gandara HJ Kung O Gautschi 2009 The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells J Thorac Oncol 4 448 454 19240653 10.1097/JTO.0b013e31819c78fb
12. NA Franken HM Rodermond J Stap J Haveman C van Bree 2006 Clonogenic assay of cells in vitro Nat Protoc 1 2315 2319 17406473 10.1038/nprot.2006.339 1:CAS:528:DC%2BD2sXhtFGjtLnI
13. CG Tepper RL Vinall CB Wee L Xue XB Shi R Burich PC Mack RW de Vere White 2007 GCP-mediated growth inhibition and apoptosis of prostate cancer cells via androgen receptor-dependent and -independent mechanisms Prostate 67 521 535 17252539 10.1002/pros.20548 1:CAS:528:DC%2BD2sXlt1ahsrs%3D (Pubitemid 46536945)
14. CG Tepper JP Gregg XB Shi RL Vinall CA Baron PE Ryan PY Desprez HJ Kung RW deVere White 2005 Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells Prostate 65 375 389 16037992 10.1002/pros.20308 1:CAS:528:DC%2BD28Xoslw%3D (Pubitemid 41759970)
15. RA Irizarry B Hobbs F Collin YD Beazer-Barclay KJ Antonellis U Scherf TP Speed 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data Biostatistics 4 249 264 12925520 10.1093/biostatistics/4.2.249
16. A Subramanian P Tamayo VK Mootha S Mukherjee BL Ebert MA Gillette A Paulovich SL Pomeroy TR Golub ES Lander JP Mesirov 2005 Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles Proc Natl Acad Sci USA 102 15545 15550 16199517 10.1073/pnas.0506580102 1:CAS:528:DC%2BD2MXht1ShtrnO (Pubitemid 41528093)
17. L Boldrini S Gisfredi S Ursino M Lucchi A Mussi F Basolo R Pingitore G Fontanini 2005 Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations Lung Cancer 50 309 317 16125276 10.1016/j.lungcan.2005.07.002
18. D Kawanami GH Mahabeleshwar Z Lin GB Atkins A Hamik SM Haldar K Maemura JC Lamanna MK Jain 2009 Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium J Biol Chem 284 20522 20530 19491109 10.1074/jbc.M109.025346 1:CAS:528:DC%2BD1MXovFWrsLs%3D
19. VA Carroll M Ashcroft 2006 Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway Cancer Res 66 6264 6270 16778202 10.1158/0008-5472.CAN-05-2519 1:CAS:528:DC%2BD28XlvVSktL0%3D
20. Muller PY, Janovjak H, Miserez AR, Dobbie Z (2002) Processing of gene expression data generated by quantitative real-time RT-PCR. Biotechniques 32:1372-1374(1376), 1378-1379
21. P Simon 2003 Q-Gene: processing quantitative real-time RT-PCR data Bioinformatics 19 1439 1440 12874059 10.1093/bioinformatics/btg157 1:CAS:528:DC%2BD3sXlsl2lsb0%3D (Pubitemid 36939825)
22. E Buck A Eyzaguirre E Brown F Petti S McCormack JD Haley KK Iwata NW Gibson G Griffin 2006 Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Mol Cancer Ther 5 2676 2684 17121914 10.1158/1535-7163.MCT-06-0166 1:CAS:528:DC%2BD28Xht1els7nP (Pubitemid 44848994)
23. M Crul H Rosing GJ de Klerk R Dubbelman M Traiser S Reichert NG Knebel JH Schellens JH Beijnen WW ten Bokkel Huinink 2002 Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours Eur J Cancer 38 1615 1621 12142051 10.1016/S0959-8049(02) 00127-2 1:CAS:528:DC%2BD38Xls1WisLo%3D (Pubitemid 34876501)
24. L Fu YA Kim X Wang X Wu P Yue S Lonial FR Khuri SY Sun 2009 Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy Cancer Res 69 8967 8976 19920197 10.1158/0008-5472.CAN-09-2190 1:CAS:528: DC%2BD1MXhsV2itLjN
25. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 6382953 10.1016/0065-2571(84)90007-4 1:CAS:528: DyaL2cXktlaksLk%3D
26. J Wu CS Bohanan JC Neumann JB Lingrel 2008 KLF2 transcription factor modulates blood vessel maturation through smooth muscle cell migration J Biol Chem 283 3942 3950 18063572 10.1074/jbc.M707882200 1:CAS:528: DC%2BD1cXhs1Wgtrw%3D
27. K Sako S Fukuhara T Minami T Hamakubo H Song T Kodama A Fukamizu JS Gutkind GY Koh N Mochizuki 2009 Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2 J Biol Chem 284 5592 5601 19106103 10.1074/jbc.M806928200 1:CAS:528:DC%2BD1MXitFSnurg%3D
28. Z Lin A Kumar S SenBanerjee K Staniszewski K Parmar DE Vaughan MA Gimbrone Jr V Balasubramanian G Garcia-Cardena MK Jain 2005 Kruppel-like factor 2 (KLF2) regulates endothelial thrombotic function Circ Res 96 e48 e57 15718498 10.1161/01.RES.0000159707.05637.a1 1:CAS:528:DC%2BD2MXitFCgtrw%3D
29. S Fukata K Inoue M Kamada C Kawada M Furihata Y Ohtsuki T Shuin 2005 Levels of angiogenesis and expression of angiogenesis-related genes are prognostic for organ-specific metastasis of renal cell carcinoma Cancer 103 931 942 15685621 10.1002/cncr.20887 1:CAS:528:DC%2BD2MXisVensrs%3D (Pubitemid 40270069)
30. B Konig F Steinbach B Janocha A Drynda M Stumm C Philipp EP Allhoff W Konig 1999 The differential expression of proinflammatory cytokines IL-6, IL-8 and TNF-alpha in renal cell carcinoma Anticancer Res 19 1519 1524 10365136 1:CAS:528:DyaK1MXjvFKjs7Y%3D (Pubitemid 29255638)
31. Huang D, Ding Y, Zhou M, Rini BI, Petillo D, Qian CN, Kahnoski R, Futreal PA, Furge KA, Teh BT (2010) Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 70:1063-1071
32. Jimenez-Lopez JM, Rios-Marco P, Marco C, Segovia JL, Carrasco MP (2010) Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis 9:33
33. AH van der Luit SR Vink JB Klarenbeek D Perrissoud E Solary M Verheij WJ van Blitterswijk 2007 A new class of anticancer alkylphospholipids uses lipid rafts as membrane gateways to induce apoptosis in lymphoma cells Mol Cancer Ther 6 2337 2345 17699729 10.1158/1535-7163.MCT-07-0202 (Pubitemid 47294762)
34. Z Arany SY Foo Y Ma JL Ruas A Bommi-Reddy G Girnun M Cooper D Laznik J Chinsomboon SM Rangwala KH Baek A Rosenzweig BM Spiegelman 2008 HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha Nature 451 1008 1012 18288196 10.1038/nature06613 1:CAS:528:DC%2BD1cXit1ynsr8%3D (Pubitemid 351301733)